$36.99 $1.84 per serving
Product analysis
BCQ has its clearest role in joint comfort, with boswellia and turmeric providing the main botanical contribution. The boswellia preparation is not identified closely enough to predict its effect confidently.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality32
Boswellic-acid and curcuminoid descriptions identify active compound groups without fully describing the extracts. Bromelain and quercetin also lack preparation details, limiting close quality comparisons.
Ingredient Transparency65
The listed amounts are disclosed, but some preparations remain unspecified. The proportions of the boswellia components are also undisclosed.
Value For Money27
Bromelain and turmeric are relatively costly at the full serving price. The available information does not establish the value of the other contributions.
Customer Satisfaction75
Customer ratings indicate high satisfaction. The relatively small feedback pool limits how widely that pattern can be applied.
Product Focus68
Joint comfort is a clearer purpose than routine digestive symptom relief. Bromelain's protein-breaking activity does not by itself establish a noticeable digestive benefit.
- Format
Capsule - Container
- 60 Capsule(s)
- Per serving
- $1.84
- Also available
BCQ$102.90- Customer rating
- 4.8 · 160 ratings
Goals
Impact
Moderate effect
Boswellia · 600 mg
Impact
Moderate effect
Boswellia · 600 mg
Impact
Highest effect
Bromelain · 300 mgBoswellia · 600 mg
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Boswellia serrata gum extract (Alpha Boswellic Acid, Beta Boswellic Acid) | 600 mg | |
Bromelain | 300 mg | |
Curcuma longa rhizome extract (Total Curcuminoids) | 600 mg | |
Quercetin Dihydrate | 300 mg |
Turmeric (Total Curcuminoids) · 600 mg OverallScore12
Bromelain · 300 mg OverallScore43
The serving provides 300 mg of bromelain; the whole-product price is high relative to the stated bromelain mass. GDU or MCU enzyme activity is unavailable. The botanical source is unspecified.
How this ingredient is rated
Composition and Label Disclosure36
GDU or MCU enzyme activity is unavailable. A directly declared GDU/g concentration is unavailable.
Enzyme Activity Disclosure
GDU or MCU enzyme activity is unavailable.
Declared GDU per Gram
A directly declared GDU/g concentration is unavailable.
Composition and Label Disclosure60
The serving lists 300 mg of bromelain. The botanical source is unspecified.
Declared Bromelain Mass
The declared serving amount is 300 mg of bromelain.
Botanical Source Disclosure
The botanical source is unspecified.
Commercial Price and Usability20
The whole-product price is high relative to the stated bromelain mass.
Cost per 500 mg Declared Bromelain
The whole-product price is high relative to the stated bromelain mass.
A serving provides 600 mg of Boswellia serrata gum extract. The boswellic acid content is unknown. No ingredient value conclusion is available.
How this ingredient is rated
Composition and Label Disclosure0
The boswellic acid content is unknown.
Marker and Preparation Disclosure
The boswellic acid content is unknown.
Composition and Label Disclosure60
The boswellia amount is stated.
Boswellia Amount and Marker Disclosure
The boswellia amount is stated.
Commercial Price and Usability
Ingredient value could not be determined.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Positive Effects of a Lecithin-Based Delivery Form of Boswellia serrata Extract in Acute Diarrhea of Adult Subjects.
- Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal.
- Supplementation with a lecithin-based delivery form of Boswellia serrata extract (Casperome®) controls symptoms of mild irritable bowel syndrome.
- Interventions for treating collagenous colitis.
- Interventions for treating collagenous colitis.
- The role of enzyme supplementation in digestive disorders.
- Effects of bromelain supplementation on disease activity and quality of life in patients with ulcerative colitis: a randomized, triple-blind, placebo-controlled study.
- Clinical Benefits of Boswellia Serrata (BOSMAX®) in Early Knee Osteoarthritis: A Randomized, Placebo-Controlled, Double-Blind Study.
- A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee.
- Boswellic Acids Improve Clinical Cognitive Scores and Reduce Systemic Inflammation in Patients with Mild to Moderate Alzheimer's Disease.
- A Standardized Boswellia serrata Extract Improves Knee Joint Function and Cartilage Morphology in Human Volunteers with Mild to Moderate Osteoarthritis in a Randomized Placebo-Controlled Study.
- A standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days-a double-blind, randomized, three-arm, parallel-group, multi-center, placebo-controlled trial.
- Therapeutic efficacy of bromelain in impacted third molar surgery: a randomized controlled clinical study.
- Efficacy of proteolytic enzyme bromelain on health outcomes after third molar surgery. Systematic review and meta-analysis of randomized clinical trials.
- Placebo-controlled randomized clinical trial on the immunomodulating activities of low- and high-dose bromelain after oral administration - new evidence on the antiinflammatory mode of action of bromelain.
- An Evaluation of the Effects of Pineapple-Extract and Bromelain-Based Treatment after Mandibular Third Molar Surgery: A Randomized Three-Arm Clinical Study.
- Therapeutic uses of pineapple-extracted bromelain in surgical care - A review.
- Oral herbal therapies for treating osteoarthritis.
- Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study.
- A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee.